BeiGene, MEI pair BTK, PI3K for blood cancers



Chinese biotech BeiGene Ltd (Nasdaq: BGNE; HKEX: 06160) and San Diego-based MEI Pharma Inc., are pairing up respective pipeline molecules to try out a new combination therapy for B-cell malignancies. BeiGene brings the Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib for a match up with MEI’s ME-401, a phosphatidylinositol 3-kinase (Pl3K) delta inhibitor.

Under the deal terms, an ongoing Phase Ib trial for ME-401 will be expanded to include evaluation of the combination with zanubrutinib in patients with B-cell malignancies. Development costs will be shared equally between the two firms, with both companies retaining all commercial rights to their respective products.

Both product candidates are potentially differentiated from other drugs in their respective classes. Zanubrutinib is BeiGene’s leading pipeline candidate, viewed as a potential best-in-class BTK inhibitor, and currently in a global Phase III study for Waldenström's macroglobulinemia. Meanwhile, ME-401 has unique pharmaceutical properties and is highly selective for PI3K delta, and is set to start a Phase II study seeking accelerated approval in the U.S. as a third-line treatment for follicular lymphoma.
Reference:
BTK

Related news
China-based biotech BeiGene Ltd, (Nasdaq:BGNE; HKEX:06160) presented encouraging early data from a Phase I trial assessing the Bruton’s tyrosine kinase (BTK) inhibitor zanbrutinib in Chinese patients with B-cell lymphoma.
  • 1537856780447
  • China
  • Drug
Beijing-based biotech BeiGene became made its first New Drug Application (NDA) for the programmed death-1 (PD-1) drug candidate tislelizumab, announcing formal acceptance for the filing by the China National Drug Application (CNDA).
  • 1535941783503
  • China
  • Drug
China-based BeiGene, a biotech company focused on cancer therapies, announced that the China National Drug Administration (CNDA) has accepted for review its New Drug Application (NDA) in relation to drug candidate zanubrutinib (BGB-3111).
  • 1535347587385
  • China
  • Drug
China-based biotech BeiGene (Nasdaq:BGNE) presented data last week illustrating the strong performance of its BTK inhibitor zanubrutinib in clinical trials treating Waldenström macroglobulinemia (WM), a type of non-Hodgkin lymphoma.
China-based biotech BeiGene Ltd, (NASDQ:BGNE) announced a deal with U.S.-based Mirati Therapeutics (NASDAQ:MRTX) to take exclusive development, manufacturing, and commercialization rights to the latter’s multi-kinase inhibitor sitravatinib.
Recent news
by JULETT PINEDA SLEINAN | @JULEPINEDA Los precios acordados de 56 principios activos ya entraron en vigencia.
Brazil's National Agency of Health Surveillance (ANVISA) has approved the combined use of Bristol-Myers Squibb's programmed death-1 (PD-1) inhibitor Opdivo (nivolumab) with the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-targeted Yervoy (ipilimumab) as a first-line therapy for untreated patients with intermediate- and poor-risk advanced or metastatic kidney cancer.
Quarta, 17 Outubro 2018 16:47 Escrito ou enviado por Catarina Marrao Uso de Opdivo (nivolumabe) associado a Yervoy (ipilimumabe) é o primeiro e o único tratamento a proporcionar aumento significativo de sobrevida global a pacientes com câncer renal metastático A biofarmacêutica global Bristol-Myers Squibb acaba de obter a aprovação da Agência Nacional de Vigilância Sanitária (ANVISA) para o uso combinado de seus imuno-oncológicos, Opdivo (nivolumabe) e Yervoy (ipilimumabe), como primeira linha de tratamento para pacientes com câncer renal avançado ou metastático de risco intermediário ou alto, não tratados previamente. Esta aprovação representa uma chance a mais para os pacientes que enfrentam a doença no brasil, tornando-se a única combinação aprovada de imunoterápicos para esta indicação em primeira linha de tratamento.
Brazil's National Health Surveillance Agency (ANVISA) approved a new therapeutic indication for Amgen's osteoporosis drug Xgeva (denosumab) to prevent skeletal problems in multiple myeloma (MM) patients.
São Paulo, 16 de outubro de 2018 - A Agência Nacional de Vigilância Sanitária (ANVISA) acaba de aprovar mais uma indicação para o Xgeva® (denosumabe), da biofarmaceutica Amgen.
Por Economidia 17 out 2018, 11h50 Entre os dias 09 e 11 de outubro de 2018, em Madri, Espanha, aconteceu a CPhI Worldwide, maior feira de negócios da indústria farmacêutica no mundo.
Brazil's National Health Surveillance Agency (ANVISA) has green lit Sanofi Pasteur's influenza vaccine Fluzone Sênior designed for people aged 65 and older, concluding an evaluation that started last year, as GBI reported.
Analytics Snapshot


Actionable intelligence at your fingertips.